Core Insights - Thermo Fisher Scientific (TMO) has expanded its Gibco Bacto CD portfolio with the introduction of Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed (2X), aimed at enhancing plasmid DNA and recombinant protein production using E. coli [1][5] Company Developments - The new formulations represent a significant advancement in microbial bioprocessing technology, expected to strengthen TMO's Cell Culture and Cell Therapy business [2] - Following the announcement, TMO shares increased by 0.7%, closing at $575.91, indicating positive market reception [3] - TMO has a market capitalization of $215.01 billion and an earnings yield of 3.9%, outperforming the industry average of -3.5% [4] Product Features - The Gibco Bacto CD Supreme FPM Plus medium is hydrolysate-free and supports high-density E. coli cultures, designed for various strains, enhancing process development and growth performance [6] - When used with Bacto CD Supreme Feed (2X), customers can achieve up to 120% higher plasmid DNA production yield compared to traditional methods, ensuring consistent results from lab to commercial scale [8][9] Industry Context - The global plasmid DNA manufacturing market is projected to grow from $2.13 billion in 2024 at a CAGR of 21.4% through 2030, driven by increasing demand for gene therapy and mRNA vaccines [10] - TMO is expanding its bioprocessing capabilities in Asia, including a new Bioprocess Design Center in Hyderabad, India, to support the growing biopharmaceutical industry [11] Stock Performance - Over the past three months, TMO shares have risen by 21.8%, significantly outperforming the industry growth of 7.5% [12]